Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 4374671, 16 pages
http://dx.doi.org/10.1155/2016/4374671
Review Article

Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences

School of Physical Education and Sport, University of São Paulo, 05508-030 São Paulo, SP, Brazil

Received 25 July 2015; Accepted 29 September 2015

Academic Editor: Matthew C. Zimmerman

Copyright © 2016 Aline V. Bacurau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Lindenfeld, N. M. Albert, J. P. Boehmer et al., “HFSA 2010 comprehensive heart failure practice guideline,” Journal of Cardiac Failure, vol. 16, pp. e1–e194, 2010. View at Google Scholar
  2. J. Farkas, S. von Haehling, K. Kalantar-Zadeh, J. E. Morley, S. D. Anker, and M. Lainscak, “Cachexia as a major public health problem: frequent, costly, and deadly,” Journal of Cachexia, Sarcopenia and Muscle, vol. 4, no. 3, pp. 173–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. E. Morley, D. R. Thomas, and M.-M. G. Wilson, “Cachexia: pathophysiology and clinical relevance,” The American Journal of Clinical Nutrition, vol. 83, no. 4, pp. 735–743, 2006. View at Google Scholar · View at Scopus
  4. S. von Haehling and S. D. Anker, “Cachexia as a major underestimated and unmet medical need: facts and numbers,” Journal of Cachexia, Sarcopenia and Muscle, vol. 1, no. 1, pp. 1–5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. von Haehling and S. D. Anker, “Cachexia vs obesity: where is the real unmet clinical need?” Journal of Cachexia, Sarcopenia and Muscle, vol. 4, no. 4, pp. 245–246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. P. C. Brum, A. V. N. Bacurau, A. Medeiros, J. C. B. Ferreira, A. S. Vanzelli, and C. E. Negrão, “Aerobic exercise training in heart failure: impact on sympathetic hyperactivity and cardiac and skeletal muscle function,” Brazilian Journal of Medical and Biological Research, vol. 44, no. 9, pp. 827–835, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. E. Negrao and H. R. Middlekauff, “Adaptations in autonomic function during exercise training in heart failure,” Heart Failure Reviews, vol. 13, no. 1, pp. 51–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. P. Lipkin, D. A. Jones, J. M. Round, and P. A. Poole-Wilson, “Abnormalities of skeletal muscle in patients with chronic heart failure,” International Journal of Cardiology, vol. 18, no. 2, pp. 187–195, 1988. View at Publisher · View at Google Scholar · View at Scopus
  9. C. C. Lang, G. H. Rayos, D. B. Chomsky, A. J. J. Wood, and J. R. Wilson, “Effect of sympathoinhibition on exercise performance in patients with heart failure,” Circulation, vol. 96, no. 1, pp. 238–245, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. H. R. Middlekauff, “Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure,” Circulation: Heart Failure, vol. 3, no. 4, pp. 537–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. R. G. Bechara, J. B. N. Moreira, P. R. Jannig et al., “NADPH oxidase hyperactivity induces plantaris atrophy in heart failure rats,” International Journal of Cardiology, vol. 175, no. 3, pp. 499–507, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. P. K. Singal, N. Kapur, K. S. Dhillon, R. E. Beamish, and N. S. Dhalla, “Role of free radicals in catecholamine-induced cardiomyopathy,” Canadian Journal of Physiology and Pharmacology, vol. 60, no. 11, pp. 1390–1397, 1982. View at Publisher · View at Google Scholar · View at Scopus
  13. P. K. Singal, R. E. Beamish, and N. S. Dhalla, “Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease,” Advances in Experimental Medicine and Biology, vol. 161, pp. 391–401, 1983. View at Publisher · View at Google Scholar · View at Scopus
  14. J. K. Shoemaker, H. L. Naylor, C. S. Hogeman, and L. I. Sinoway, “Blood flow dynamics in heart failure,” Circulation, vol. 99, no. 23, pp. 3002–3008, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. C. E. Negrão, M. U. P. Brandão Rondon, T. Tinucci et al., “Abnormal neurovascular control during exercise is linked to heart failure severity,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 280, no. 3, pp. H1286–H1292, 2001. View at Google Scholar · View at Scopus
  16. M. F. Piepoli, K. Dimopoulos, A. Concu, and A. Crisafulli, “Cardiovascular and ventilatory control during exercise in chronic heart failure: role of muscle reflexes,” International Journal of Cardiology, vol. 130, no. 1, pp. 3–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. F. Piepoli, A. C. Scott, A. Capucci, and A. J. S. Coats, “Skeletal muscle training in chronic heart failure,” Acta Physiologica Scandinavica, vol. 171, no. 3, pp. 295–303, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. M. F. Piepoli and A. J. S. Coats, “The ‘skeletal muscle hypothesis in heart failure’ revised,” European Heart Journal, vol. 34, no. 7, pp. 486–488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. J. S. Floras, “Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure,” Journal of the American College of Cardiology, vol. 22, supplement 1, no. 4, pp. A72–A84, 1993. View at Publisher · View at Google Scholar · View at Scopus
  20. T. F. Cunha, A. V. N. Bacurau, J. B. N. Moreira et al., “Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure,” PLoS ONE, vol. 7, no. 8, Article ID e41701, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Gielen, M. Sandri, I. Kozarez et al., “Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized leipzig exercise intervention in chronic heart failure and aging catabolism study,” Circulation, vol. 125, no. 22, pp. 2716–2727, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. V. M. Conraads, P. Beckers, J. Bosmans et al., “Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease,” European Heart Journal, vol. 23, no. 23, pp. 1854–1860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Gielen, V. Adams, S. Möbius-Winkler et al., “Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure,” Journal of the American College of Cardiology, vol. 42, no. 5, pp. 861–868, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Fraga, F. G. Franco, F. Roveda et al., “Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol,” European Journal of Heart Failure, vol. 9, no. 6-7, pp. 630–636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Roveda, H. R. Middlekauff, M. U. P. B. Rondon et al., “The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial,” Journal of the American College of Cardiology, vol. 42, no. 5, pp. 854–860, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. A. J. S. Coats, A. L. Clark, M. Piepoli, M. Volterrani, and P. A. Poole-Wilson, “Symptoms and quality of life in heart failure: the muscle hypothesis,” British Heart Journal, vol. 72, no. 2, pp. S36–S39, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Medeiros, N. P. L. Rolim, R. S. F. Oliveira et al., “Exercise training delays cardiac dysfunction and prevents calcium handling abnormalities in sympathetic hyperactivity-induced heart failure mice,” Journal of Applied Physiology, vol. 104, no. 1, pp. 103–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. I. L. Gomes-Santos, T. Fernandes, G. K. Couto et al., “Effects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure rats,” PLoS ONE, vol. 9, no. 5, Article ID e98012, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. A. V. N. Bacurau, M. A. Jardim, J. C. B. Ferreira et al., “Sympathetic hyperactivity differentially affects skeletal muscle mass in developing heart failure: role of exercise training,” Journal of Applied Physiology, vol. 106, no. 5, pp. 1631–1640, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. J. Peters, D. J. Dyck, A. Bonen, and L. L. Spriet, “Effects of epinephrine on lipid metabolism in resting skeletal muscle,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 275, no. 2, pp. E300–E309, 1998. View at Google Scholar · View at Scopus
  31. J. H. Williams and W. S. Barnes, “The positive inotropic effect of epinephrine on skeletal muscle: a brief review,” Muscle and Nerve, vol. 12, no. 12, pp. 968–975, 1989. View at Publisher · View at Google Scholar · View at Scopus
  32. M. S. Elfellah, R. Dalling, I. M. Kantola, and J. L. Reid, “β-adrenoceptors and human skeletal muscle characterisation of receptor subtype and effect of age,” British Journal of Clinical Pharmacology, vol. 27, no. 1, pp. 31–38, 1989. View at Publisher · View at Google Scholar · View at Scopus
  33. S. B. Liggett, S. D. Shah, and P. E. Cryer, “Increased fat and skeletal muscle beta-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis,” The Journal of Clinical Investigation, vol. 83, no. 3, pp. 803–809, 1989. View at Publisher · View at Google Scholar · View at Scopus
  34. O. A. Coman, H. Păunescu, I. Ghiţă, L. Coman, A. Bădărăru, and I. Fulga, “Beta 3 adrenergic receptors: molecular, histological, functional and pharmacological approaches,” Romanian Journal of Morphology and Embryology, vol. 50, no. 2, pp. 169–179, 2009. View at Google Scholar · View at Scopus
  35. J. Jensen, O. Brors, and H. A. Dahl, “Different β-adrenergic receptor density in different rat skeletal muscle fibre types,” Pharmacology and Toxicology, vol. 76, no. 6, pp. 380–385, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. S. Kim, R. D. Sainz, P. Molenaar, and R. J. Summers, “Characterization of β1- and β2-adrenoceptors in rat skeletal muscles,” Biochemical Pharmacology, vol. 42, no. 9, pp. 1783–1789, 1991. View at Publisher · View at Google Scholar · View at Scopus
  37. W. H. Martin III, S. Murphree, and J. E. Saffitz, “beta-adrenergic receptor distribution among muscle fiber types and resistance arterioles of white, red, and intermediate skeletal muscle,” Circulation Research, vol. 64, no. 6, pp. 1096–1105, 1989. View at Publisher · View at Google Scholar · View at Scopus
  38. J. G. Ryall, P. Gregorevic, D. R. Plant, M. N. Sillence, and G. S. Lynch, “β2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 283, no. 6, pp. R1386–R1394, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. J. G. Ryall, D. R. Plant, P. Gregorevic, M. N. Sillence, and G. S. Lynch, “β2-agonist administration reverses muscle wasting and improves muscle function in aged rats,” Journal of Physiology, vol. 555, no. 1, pp. 175–188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. S. Kim, R. D. Sainz, R. J. Summers, and P. Molenaar, “Cimaterol reduces beta-adrenergic receptor density in rat skeletal muscles,” Journal of Animal Science, vol. 70, no. 1, pp. 115–122, 1992. View at Google Scholar · View at Scopus
  41. J. Jensen, E. O. Brennesvik, L. H. Bergersen, H. Oseland, E. Jebens, and O. Brørs, “Quantitative determination of cell surface β-adrenoceptors in different rat skeletal muscles,” Pflugers Archiv, vol. 444, no. 1-2, pp. 213–219, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. J. G. Ryall, M. N. Sillence, and G. S. Lynch, “Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses,” British Journal of Pharmacology, vol. 147, no. 6, pp. 587–595, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Hagström-Toft, S. Enoksson, E. Moberg, J. Bolinder, and P. Arner, “β-adrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo,” American Journal of Physiology: Endocrinology and Metabolism, vol. 275, no. 6, pp. E909–E916, 1998. View at Google Scholar · View at Scopus
  44. J. Hoeks, M. A. van Baak, M. K. C. Hesselink et al., “Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 285, no. 4, pp. E775–E782, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. M. R. Dietz, J. L. Chiasson, T. R. Soderling, and J. H. Exton, “Epinephrine regulation of skeletal muscle glycogen metabolism. Studies utilizing the perfused rat hindlimb preparation,” Journal of Biological Chemistry, vol. 255, no. 6, pp. 2301–2307, 1980. View at Google Scholar · View at Scopus
  46. I. Raz, A. Katz, and M. K. Spencer, “Epinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 260, no. 3, pp. E430–E435, 1991. View at Google Scholar · View at Scopus
  47. A. I. Öberg, β-adrenergic signalling and novel effects in skeletal muscle [Ph.D. thesis], Stockholm University, Stockholm, Sweden, 2013.
  48. G. W. Fernandes, C. B. Ueta, T. L. Fonseca et al., “Inactivation of the adrenergic receptor β2 disrupts glucose homeostasis in mice,” Journal of Endocrinology, vol. 221, no. 3, pp. 381–390, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Schmid, J.-F. Renaud, and M. Lazdunski, “Short term and long term effects of β-adrenergic effectors and cyclic AMP on nitrendipine-sensitive voltage-dependent Ca2+ channels of skeletal muscle,” The Journal of Biological Chemistry, vol. 260, no. 24, pp. 13041–13046, 1985. View at Google Scholar · View at Scopus
  50. J. Suko, I. Maurer-Fogy, B. Plank et al., “Phosphorylation of serine 2843 in ryanodine receptor-calcium release channel of skeletal muscle by cAMP-, cGMP- and CaM-dependent protein kinase,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1175, no. 2, pp. 193–206, 1993. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Tadaishi, S. Miura, Y. Kai et al., “Effect of exercise intensity and AICAR on isoform-specific expressions of murine skeletal muscle PGC-1α mRNA: a role of β2-adrenergic receptor activation,” American Journal of Physiology: Endocrinology and Metabolism, vol. 300, no. 2, pp. E341–E349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Miura, Y. Kai, Y. Kamei, and O. Ezaki, “Isoform-specific increases in murine skeletal muscle peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) mRNA in response to β2-adrenergic receptor activation and exercise,” Endocrinology, vol. 149, no. 9, pp. 4527–4533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Miura, K. Kawanaka, Y. Kai et al., “An increase in murine skeletal muscle peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) mRNA in response to exercise is mediated by β-adrenergic receptor activation,” Endocrinology, vol. 148, no. 7, pp. 3441–3448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. M. Robinson, C. Bell, F. F. Peelor III, and B. F. Miller, “β-adrenergic receptor blockade blunts postexercise skeletal muscle mitochondrial protein synthesis rates in humans,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 301, no. 2, pp. R327–R334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. L. P. Wills, R. E. Trager, G. C. Beeson et al., “The β2-adrenoceptor agonist formoterol stimulates mitochondrial biogenesis,” Journal of Pharmacology and Experimental Therapeutics, vol. 342, no. 1, pp. 106–118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Valsecchi, L. S. Ramos-Espiritu, J. Buck, L. R. Levin, and G. Manfredi, “cAMP and mitochondria,” Physiology, vol. 28, no. 3, pp. 199–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. F. X. Soriano, M. Liesa, D. Bach, D. C. Chan, M. Palacín, and A. Zorzano, “Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-γ coactivator-1α, estrogen-related receptor-α, and mitofusin 2,” Diabetes, vol. 55, no. 6, pp. 1783–1791, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. O. R. Joassard, A. Amirouche, Y. S. Gallot et al., “Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 11, pp. 2444–2455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. D. De Rasmo, G. Gattoni, F. Papa et al., “The β-adrenoceptor agonist isoproterenol promotes the activity of respiratory chain complex I and lowers cellular reactive oxygen species in fibroblasts and heart myoblasts,” European Journal of Pharmacology, vol. 652, no. 1–3, pp. 15–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. R. K. Dagda, A. M. Gusdon, I. Pien et al., “Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson's disease,” Cell Death & Differentiation, vol. 18, no. 12, pp. 1914–1923, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Busquets, M. T. Figueras, G. Fuster et al., “Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting,” Cancer Research, vol. 64, no. 18, pp. 6725–6731, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. M. T. Silva, L. A. Wensing, P. C. Brum, N. O. Camara, and E. H. Miyabara, “Impaired structural and functional regeneration of skeletal muscles from β2-adrenoceptor knockout mice,” Acta Physiologica, vol. 211, no. 4, pp. 617–633, 2014. View at Publisher · View at Google Scholar
  63. S. W. Jones, D. J. Baker, and P. L. Greenhaff, “G protein-coupled receptor kinases 2 and 5 are differentially expressed in rat skeletal muscle and remain unchanged following β2-agonist administration,” Experimental Physiology, vol. 88, no. 2, pp. 277–284, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. G. S. Lynch and J. G. Ryall, “Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease,” Physiological Reviews, vol. 88, no. 2, pp. 729–767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. L. C. C. Navegantes, R. H. Migliorini, and I. do Carmo Kettelhut, “Adrenergic control of protein metabolism in skeletal muscle,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 5, no. 3, pp. 281–286, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. T. Yang and M. A. McElligott, “Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue,” Biochemical Journal, vol. 261, no. 1, pp. 1–10, 1989. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Agrawal, P. Thakur, and S. S. Katoch, “Beta adrenoceptor agonists, clenbuterol, and isoproterenol retard denervation atrophy in rat gastrocnemius muscle: use of 3-methylhistidine as a marker of myofibrillar degeneration,” Japanese Journal of Physiology, vol. 53, no. 3, pp. 229–237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. L. C. C. Navegantes, N. M. Z. Resano, R. H. Migliorini, and Í. C. Kettelhut, “Role of adrenoceptors and cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 279, no. 3, pp. E663–E668, 2000. View at Google Scholar · View at Scopus
  69. L. C. C. Navegantes, N. M. Z. Resano, R. H. Migliorini, and I. C. Kettelhut, “Effect of guanethidine-induced adrenergic blockade on the different proteolytic systems in rat skeletal muscle,” American Journal of Physiology: Endocrinology and Metabolism, vol. 277, no. 5, pp. E883–E889, 1999. View at Google Scholar · View at Scopus
  70. P. Molenaar, L. Chen, and W. A. Parsonage, “Cardiac implications for the use of β 2-adrenoceptor agonists for the management of muscle wasting,” British Journal of Pharmacology, vol. 147, no. 6, pp. 583–586, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. I. George, S. Xydas, D. M. Mancini et al., “Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support,” Journal of Heart and Lung Transplantation, vol. 25, no. 9, pp. 1084–1090, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. V. A. Voltarelli, L. R. G. Bechara, A. V. N. Bacurau et al., “Lack of β2-adrenoceptors aggravates heart failure-induced skeletal muscle myopathy in mice,” Journal of Cellular and Molecular Medicine, vol. 18, no. 6, pp. 1087–1097, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. N. J. Rothwell, M. J. Stock, and D. K. Sudera, “Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol,” British Journal of Pharmacology, vol. 90, no. 3, pp. 601–607, 1987. View at Publisher · View at Google Scholar · View at Scopus
  74. The Consensus Trial Study Group, “Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS),” The New England Journal of Medicine, vol. 316, no. 23, pp. 1429–1435, 1987. View at Publisher · View at Google Scholar · View at Scopus
  75. The SOLVD Investigators, “Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure,” The New England Journal of Medicine, vol. 325, no. 5, pp. 293–302, 1991. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Garg and S. Yusuf, “Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure,” The Journal of the American Medical Association, vol. 273, no. 18, pp. 1450–1456, 1995. View at Publisher · View at Google Scholar · View at Scopus
  77. C. M. Ferrario and W. B. Strawn, “Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease,” American Journal of Cardiology, vol. 98, no. 1, pp. 121–128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. R. J. Mentz, G. L. Bakris, B. Waeber et al., “The past, present and future of renin-angiotensin aldosterone system inhibition,” International Journal of Cardiology, vol. 167, no. 5, pp. 1677–1687, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. S. D. Anker, A. Negassa, A. J. S. Coats et al., “Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study,” The Lancet, vol. 361, no. 9363, pp. 1077–1083, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Yoshida and P. Delafontaine, “Mechanisms of cachexia in chronic disease states,” The American Journal of the Medical Sciences, 2015. View at Publisher · View at Google Scholar
  81. W. J. Evans, J. E. Morley, J. Argilés et al., “Cachexia: a new definition,” Clinical Nutrition, vol. 27, no. 6, pp. 793–799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. P. E. Ward, J. S. Russell, and P. L. Vaghy, “Angiotensin and bradykinin metabolism by peptidases identified in skeletal muscle,” Peptides, vol. 16, no. 6, pp. 1073–1078, 1995. View at Publisher · View at Google Scholar · View at Scopus
  83. A. P. W. Johnston, J. Baker, M. De Lisio, and G. Parise, “Skeletal muscle myoblasts possess a stretch-responsive local angiotensin signalling system,” Journal of Renin-Angiotensin-Aldosterone System, vol. 12, no. 2, pp. 75–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Brink, J. Wellen, and P. Delafontaine, “Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism,” The Journal of Clinical Investigation, vol. 97, no. 11, pp. 2509–2516, 1996. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Brink, S. R. Price, J. Chrast et al., “Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I,” Endocrinology, vol. 142, no. 4, pp. 1489–1496, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. F. Folli, C. R. Kahn, H. Hansen, J. L. Bouchie, and E. P. Feener, “Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk,” The Journal of Clinical Investigation, vol. 100, no. 9, pp. 2158–2169, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. L. A. Velloso, F. Folli, L. Perego, and M. J. A. Saad, “The multi-faceted cross-talk between the insulin and angiotensin II signaling systems,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 2, pp. 98–107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. Y.-H. Song, Y. Li, J. Du, W. E. Mitch, N. Rosenthal, and P. Delafontaine, “Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting,” The Journal of Clinical Investigation, vol. 115, no. 2, pp. 451–458, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. C. Werner, J. Pöss, and M. Böhm, “Optimal antagonism of the renin-angiotensin-aldosterone system: do we need dual or triple therapy?” Drugs, vol. 70, no. 10, pp. 1215–1230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. T. Yoshida, L. Semprun-Prieto, S. Sukhanov, and P. Delafontaine, “IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 298, no. 5, pp. H1565–H1570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. L. C. Semprun-Prieto, S. Sukhanov, T. Yoshida et al., “Angiotensin II induced catabolic effect and muscle atrophy are redox dependent,” Biochemical and Biophysical Research Communications, vol. 409, no. 2, pp. 217–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Yoshida, S. Galvez, S. Tiwari et al., “Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration,” The Journal of Biological Chemistry, vol. 288, no. 33, pp. 23823–23832, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. T. Yoshida, A. M. Tabony, S. Galvez et al., “Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 10, pp. 2322–2332, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. A. M. Tabony, T. Yoshida, S. Galvez et al., “Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting,” Hypertension, vol. 58, no. 4, pp. 643–649, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. F. L. Muller, W. Song, Y. C. Jang et al., “Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 293, no. 3, pp. R1159–R1168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. N. P. Whitehead, E. W. Yeung, S. C. Froehner, and D. G. Allen, “Skeletal muscle NADPH oxidase is increased and triggers stretch-induced damage in the mdx mouse,” PLoS ONE, vol. 5, no. 12, Article ID e15354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Zhang, J. Du, Z. Hu et al., “IL-6 and serum amyloid A synergy mediates angiotensin ll-Lnduced muscle wasting,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. L. Dalla Libera, B. Ravara, A. Angelini et al., “Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure,” Circulation, vol. 103, no. 17, pp. 2195–2200, 2001. View at Publisher · View at Google Scholar · View at Scopus
  99. G. Onder, B. W. J. H. Penninx, R. Balkrishnan et al., “Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study,” The Lancet, vol. 359, no. 9310, pp. 926–930, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Sumukadas, M. D. Witham, A. D. Struthers, and M. E. T. McMurdo, “Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial,” Canadian Medical Association Journal, vol. 177, no. 8, pp. 867–874, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Coirault, A. Hagège, D. Chemla, M.-D. Fratacci, C. Guérot, and Y. Lecarpentier, “Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure,” Chest, vol. 119, no. 6, pp. 1755–1760, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Zoll, L. Monassier, A. Garnier et al., “ACE inhibition prevents myocardial infarction-induced skeletal muscle mitochondrial dysfunction,” Journal of Applied Physiology, vol. 101, no. 2, pp. 385–391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. X. Feng, Z. Luo, L. Ma et al., “Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway,” Journal of Cellular and Molecular Medicine, vol. 15, no. 7, pp. 1572–1581, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. G. Lastra, F. R. Santos, P. Hooshmand et al., “The novel angiotensin II receptor blocker azilsartan medoxomil ameliorates insulin resistance induced by chronic angiotensin II treatment in rat skeletal muscle,” Cardiorenal Medicine, vol. 3, no. 2, pp. 154–164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. J. G. Burniston, A. Saini, L.-B. Tan, and D. F. Goldspink, “Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo,” Journal of Molecular and Cellular Cardiology, vol. 39, no. 2, pp. 395–399, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Cheema, W. Zhao, T. Zhao et al., “Reverse remodeling and recovery from cachexia in rats with aldosteronism,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 303, no. 4, pp. H486–H495, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. L. A. Burton, M. E. T. McMurdo, and A. D. Struthers, “Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?” Clinical Endocrinology, vol. 75, no. 6, pp. 725–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. T. Yoshida, T. S. Huq, and P. Delafontaine, “Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration,” The Journal of Biological Chemistry, vol. 289, no. 38, pp. 26239–26248, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. R. A. S. Santos, A. C. Simoes e Silva, C. Maric et al., “Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8258–8263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Vickers, P. Hales, V. Kaushik et al., “Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase,” Journal of Biological Chemistry, vol. 277, no. 17, pp. 14838–14843, 2002. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Fernandes, N. Y. Hashimoto, and E. M. Oliveira, “Characterization of angiotensin-converting enzymes 1 and 2 in the soleus and plantaris muscles of rats,” Brazilian Journal of Medical and Biological Research, vol. 43, no. 9, pp. 837–842, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Prasannarong, F. R. Santos, and E. J. Henriksen, “ANG-(1-7) reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle,” Biochemical and Biophysical Research Communications, vol. 426, no. 3, pp. 369–373, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. J. Fang, J. Wylie-Rosett, H. W. Cohen, R. C. Kaplan, and M. H. Alderman, “Exercise, body mass index, caloric intake, and cardiovascular mortality,” American Journal of Preventive Medicine, vol. 25, no. 4, pp. 283–289, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. R. J. Sigal, G. P. Kenny, D. H. Wasserman, and C. Castaneda-Sceppa, “Physical activity/exercise and type 2 diabetes,” Diabetes Care, vol. 27, no. 10, pp. 2518–2539, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. S. K. Powers, “Exercise, antioxidants, and cardioprotection,” Sports Science Exchange, vol. 15, no. 2, p. 85, 2002. View at Google Scholar
  116. C. A. Emter, S. A. McCune, G. C. Sparagna, M. J. Radin, and R. L. Moore, “Low-intensity exercise training delays onset of decompensated heart failure in spontaneously hypertensive heart failure rats,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 289, no. 5, pp. H2030–H2038, 2005. View at Publisher · View at Google Scholar · View at Scopus
  117. S. Jónsdóttir, K. K. Andersen, A. F. Sigurosson, and S. B. Sigurosson, “The effect of physical training in chronic heart failure,” European Journal of Heart Failure, vol. 8, no. 1, pp. 97–101, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. K. Dickstein, A. Cohen-Solal, G. Filippatos et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM),” European Journal of Heart Failure, vol. 10, no. 10, pp. 933–989, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. S. A. Hunt, W. T. Abraham, M. H. Chin et al., “2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation,” Circulation, vol. 119, no. 14, pp. e391–e479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. V. Adams and J. Niebauer, “Reversing heart failure-associated pathophysiology with exercise: what actually improves and by how much?” Heart Failure Clinics, vol. 11, no. 1, pp. 17–28, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. E. De Sousa, V. Veksler, X. Bigard, P. M. Bing, and R. Ventura-Clapier, “Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle,” Circulation, vol. 102, no. 15, pp. 1847–1853, 2000. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Garnier, D. Fortin, C. Deloménie, I. Momken, V. Veksler, and R. Ventura-Clapier, “Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles,” The Journal of Physiology, vol. 551, no. 2, pp. 491–501, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. P. K. Lunde, I. Sjaastad, H.-M. Schiøtz Thorud, and O. M. Sejersted, “Skeletal muscle disorders in heart failure,” Acta Physiologica Scandinavica, vol. 171, no. 3, pp. 277–294, 2001. View at Publisher · View at Google Scholar · View at Scopus
  124. B. Massie, M. Conway, R. Yonge et al., “Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow,” Circulation, vol. 76, no. 5, pp. 1009–1019, 1987. View at Publisher · View at Google Scholar · View at Scopus
  125. M. F. Piepoli, “Exercise training in chronic heart failure: mechanisms and therapies,” Netherlands Heart Journal, vol. 21, no. 2, pp. 85–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. R. W. A. Souza, W. P. Piedade, L. C. Soares et al., “Aerobic exercise training prevents heart failure-induced skeletal muscle atrophy by anti-catabolic, but not anabolic actions,” PLoS ONE, vol. 9, no. 10, Article ID e110020, 2014. View at Publisher · View at Google Scholar · View at Scopus
  127. G. Vescovo, B. Ravara, V. Gobbo, A. Angelini, and L. Dalla Libera, “Skeletal muscle fibres synthesis in heart failure: role of PGC-1alpha, calcineurin and GH,” International Journal of Cardiology, vol. 104, no. 3, pp. 298–306, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. G. Vescovo, M. Volterrani, R. Zennaro et al., “Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes,” Heart, vol. 84, no. 4, pp. 431–437, 2000. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Ohtsubo, K. Yonezawa, H. Nishijima et al., “Metabolic abnormality of calf skeletal muscle is improved by localised muscle training without changes in blood flow in chronic heart failure,” Heart, vol. 78, no. 5, pp. 437–443, 1997. View at Publisher · View at Google Scholar · View at Scopus
  130. J. R. Stratton, W. C. Levy, M. D. Cerqueira, R. S. Schwartz, and I. B. Abrass, “Cardiovascular responses to exercise. Effects of aging and exercise training in healthy men,” Circulation, vol. 89, no. 4, pp. 1648–1655, 1994. View at Publisher · View at Google Scholar · View at Scopus
  131. F. Brunotte, C. H. Thompson, S. Adamopoulos et al., “Rat skeletal muscle metabolism in experimental heart failure: effects of physical training,” Acta Physiologica Scandinavica, vol. 154, no. 4, pp. 439–447, 1995. View at Publisher · View at Google Scholar · View at Scopus
  132. R. Hambrecht, V. Adams, S. Gielen et al., “Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle,” Journal of the American College of Cardiology, vol. 33, no. 1, pp. 174–179, 1999. View at Publisher · View at Google Scholar · View at Scopus
  133. R. Hambrecht, J. Niebauer, E. Fiehn et al., “Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles,” Journal of the American College of Cardiology, vol. 25, no. 6, pp. 1239–1249, 1995. View at Publisher · View at Google Scholar · View at Scopus
  134. R. Hambrecht, E. Fiehn, J. Yu et al., “Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure,” Journal of the American College of Cardiology, vol. 29, no. 5, pp. 1067–1073, 1997. View at Publisher · View at Google Scholar · View at Scopus
  135. C. L. Perreault, H. Gonzalez-Serratos, S. E. Litwin, X. Sun, C. Franzini-Armstrong, and J. P. Morgan, “Alterations in contractility and intracellular Ca2+ transients in isolated bundles of skeletal muscle fibers from rats with chronic heart failure,” Circulation Research, vol. 73, no. 2, pp. 405–412, 1993. View at Publisher · View at Google Scholar · View at Scopus
  136. H. R. Middlekauff, C. Vigna, M. A. Verity et al., “Abnormalities of calcium handling proteins in skeletal muscle mirror those of the heart in humans with heart failure: a shared mechanism?” Journal of Cardiac Failure, vol. 18, no. 9, pp. 724–733, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. C. R. Bueno Jr., J. C. B. Ferreira, M. G. Pereira, A. V. N. Bacurau, and P. C. Brum, “Aerobic exercise training improves skeletal muscle function and Ca2+ handling-related protein expression in sympathetic hyperactivity-induced heart failure,” Journal of Applied Physiology, vol. 109, no. 3, pp. 702–709, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. M. Munkvik, T. A. Rehn, G. SlettalØkken et al., “Training effects on skeletal muscle calcium handling in human chronic heart failure,” Medicine and Science in Sports and Exercise, vol. 42, no. 5, pp. 847–855, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. S. D. Anker, P. Ponikowski, S. Varney et al., “Wasting as independent risk factor for mortality in chronic heart failure,” The Lancet, vol. 349, no. 9058, pp. 1050–1053, 1997. View at Publisher · View at Google Scholar
  140. L. Dalla Libera, R. Sabbadini, C. Renken et al., “Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 10, pp. 1871–1878, 2001. View at Publisher · View at Google Scholar · View at Scopus
  141. A. Linke, V. Adams, P. C. Schulze et al., “Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle,” Circulation, vol. 111, no. 14, pp. 1763–1770, 2005. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Cicoira, A. P. Bolger, W. Doehner et al., “High tumour necrosis factor-α levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients,” Cytokine, vol. 15, no. 2, pp. 80–86, 2001. View at Publisher · View at Google Scholar · View at Scopus
  143. G. J. J. Silva, P. C. Brum, C. E. Negrão, and E. M. Krieger, “Acute and chronic effects of exercise on baroreflexes in spontaneously hypertensive rats,” Hypertension, vol. 30, no. 3, pp. 714–719, 1997. View at Publisher · View at Google Scholar · View at Scopus
  144. P. C. Brum, G. J. J. Da Silva, E. D. Moreira, F. Ida, C. E. Negrão, and E. M. Krieger, “Exercise training increases baroreceptor gain sensitivity in normal and hypertensive rats,” Hypertension, vol. 36, no. 6, pp. 1018–1022, 2000. View at Publisher · View at Google Scholar · View at Scopus
  145. J.-L. Liu, S. Irvine, I. A. Reid, K. P. Patel, and I. H. Zucker, “Chronic exercise reduces sympathetic nerve activity in rabbits with pacing-induced heart failure: a role for angiotensin II,” Circulation, vol. 102, no. 15, pp. 1854–1862, 2000. View at Publisher · View at Google Scholar · View at Scopus
  146. H.-J. Wang, Y.-L. Li, I. H. Zucker, and W. Wang, “Exercise training prevents skeletal muscle afferent sensitization in rats with chronic heart failure,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 302, no. 11, pp. R1260–R1270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  147. L. C. Michelini and J. E. Stern, “Exercise-induced neuronal plasticity in central autonomic networks: role in cardiovascular control,” Experimental Physiology, vol. 94, no. 9, pp. 947–960, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. S. Kar, L. Gao, and I. H. Zucker, “Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure,” Journal of Applied Physiology, vol. 108, no. 4, pp. 923–932, 2010. View at Publisher · View at Google Scholar · View at Scopus
  149. L. M. Antunes-Correa, T. S. Nobre, R. V. Groehs et al., “Molecular basis for the improvement in muscle metaboreflex and mechanoreflex control in exercise-trained humans with chronic heart failure,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 307, no. 11, pp. H1655–H1666, 2014. View at Publisher · View at Google Scholar · View at Scopus
  150. I. H. Zucker, L. Xiao, and K. K. V. Haack, “The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure,” Clinical Science, vol. 126, no. 10, pp. 695–706, 2014. View at Publisher · View at Google Scholar · View at Scopus
  151. W. Zhao, S. A. Swanson, J. Ye et al., “Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension,” Hypertension, vol. 48, no. 4, pp. 637–643, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. J. Niebauer, “Inflammatory mediators in heart failure,” International Journal of Cardiology, vol. 72, no. 3, pp. 209–213, 2000. View at Publisher · View at Google Scholar · View at Scopus
  153. S. Acharyya, K. J. Ladner, L. L. Nelsen et al., “Cancer cachexia is regulated by selective targeting of skeletal muscle gene products,” The Journal of Clinical Investigation, vol. 114, no. 3, pp. 370–378, 2004. View at Publisher · View at Google Scholar · View at Scopus
  154. S. Adamopoulos, J. Parissis, C. Kroupis et al., “Physical training reduces peripheral markers of inflammation in patients with chronic heart failure,” European Heart Journal, vol. 22, no. 9, pp. 791–797, 2001. View at Publisher · View at Google Scholar · View at Scopus
  155. N. Mangner, A. Linke, A. Oberbach et al., “Exercise training prevents TNF-alpha induced loss of force in the diaphragm of mice,” PLoS ONE, vol. 8, no. 1, Article ID e52274, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. J. S. Moylan and M. B. Reid, “Oxidative stress, chronic disease, and muscle wasting,” Muscle and Nerve, vol. 35, no. 4, pp. 411–429, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. M. C. C. Gomes-Marcondes and M. J. Tisdale, “Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress,” Cancer Letters, vol. 180, no. 1, pp. 69–74, 2002. View at Publisher · View at Google Scholar · View at Scopus
  158. Y.-P. Li, Y. Chen, A. S. Li, and M. B. Reid, “Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes,” The American Journal of Physiology—Cell Physiology, vol. 285, no. 4, pp. C806–C812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  159. J. B. N. Moreira, L. R. G. Bechara, L. H. M. Bozi et al., “High-versus moderate-intensity aerobic exercise training effects on skeletal muscle of infarcted rats,” Journal of Applied Physiology, vol. 114, no. 8, pp. 1029–1041, 2013. View at Publisher · View at Google Scholar · View at Scopus
  160. D. Attaix, L. Combaret, D. Béchet, and D. Taillandier, “Role of the ubiquitin-proteasome pathway in muscle atrophy in cachexia,” Current Opinion in Supportive and Palliative Care, vol. 2, no. 4, pp. 262–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  161. S. H. Lecker, R. T. Jagoe, A. Gilbert et al., “Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression,” The FASEB Journal, vol. 18, no. 1, pp. 39–51, 2004. View at Publisher · View at Google Scholar · View at Scopus
  162. E. Edstrom, M. Altun, M. Hägglund, and B. Ulfhake, “Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 61, no. 7, pp. 663–674, 2006. View at Google Scholar
  163. M. Sandri, C. Sandri, A. Gilbert et al., “Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy,” Cell, vol. 117, no. 3, pp. 399–412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  164. P. R. Cao, H. J. Kim, and S. H. Lecker, “Ubiquitin-protein ligases in muscle wasting,” The International Journal of Biochemistry & Cell Biology, vol. 37, no. 10, pp. 2088–2097, 2005. View at Publisher · View at Google Scholar · View at Scopus
  165. S. C. Bodine, E. Latres, S. Baumhueter et al., “Identification of ubiquitin ligases required for skeletal muscle atrophy,” Science, vol. 294, no. 5547, pp. 1704–1708, 2001. View at Publisher · View at Google Scholar · View at Scopus
  166. M. D. Gomes, S. H. Lecker, R. T. Jagoe, A. Navon, and A. L. Goldberg, “Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 25, pp. 14440–14445, 2001. View at Publisher · View at Google Scholar · View at Scopus
  167. S. C. Bodine and L. M. Baehr, “Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 307, no. 6, pp. E469–E484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  168. T. F. Cunha, J. B. N. Moreira, N. A. Paixão et al., “Aerobic exercise training upregulates skeletal muscle calpain and ubiquitin-proteasome systems in healthy mice,” Journal of Applied Physiology, vol. 112, no. 11, pp. 1839–1846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  169. M. Sandri, J. Lin, C. Handschin et al., “PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 44, pp. 16260–16265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. D. J. Glass, “Molecular mechanisms modulating muscle mass,” Trends in Molecular Medicine, vol. 9, no. 8, pp. 344–350, 2003. View at Publisher · View at Google Scholar · View at Scopus
  171. R. Hambrecht, P. C. Schulze, S. Gielen et al., “Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 12, no. 4, pp. 401–406, 2005. View at Publisher · View at Google Scholar · View at Scopus
  172. A. Musarò, K. McCullagh, A. Paul et al., “Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle,” Nature Genetics, vol. 27, no. 2, pp. 195–200, 2001. View at Publisher · View at Google Scholar · View at Scopus
  173. E. R. Barton, L. Morris, A. Musaro, N. Rosenthal, and H. L. Sweeney, “Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice,” Journal of Cell Biology, vol. 157, no. 1, pp. 137–147, 2002. View at Publisher · View at Google Scholar · View at Scopus
  174. O. Schakman, H. Gilson, V. de Coninck et al., “Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats,” Endocrinology, vol. 146, no. 4, pp. 1789–1797, 2005. View at Publisher · View at Google Scholar · View at Scopus
  175. J. E. Stevens-Lapsley, F. Ye, M. Liu et al., “Impact of viral-mediated IGF-I gene transfer on skeletal muscle following cast immobilization,” American Journal of Physiology: Endocrinology and Metabolism, vol. 299, no. 5, pp. E730–E740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  176. P. C. Schulze, J. Fang, K. A. Kassik et al., “Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction,” Circulation Research, vol. 97, no. 5, pp. 418–426, 2005. View at Publisher · View at Google Scholar · View at Scopus
  177. J. Manetta, J. F. Brun, L. Maimoun, A. Callis, C. Préfaut, and J. Mercier, “Effect of training on the GH/IGF-I axis during exercise in middle-aged men: relationship to glucose homeostasis,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 283, no. 5, pp. E929–E936, 2002. View at Publisher · View at Google Scholar · View at Scopus
  178. B. C. Nindl and J. R. Pierce, “Insulin-like growth factor i as a biomarker of health, fitness, and training status,” Medicine and Science in Sports and Exercise, vol. 42, no. 1, pp. 39–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  179. R. Hambrecht, P. C. Schulze, S. Gielen et al., “Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure,” Journal of the American College of Cardiology, vol. 39, no. 7, pp. 1175–1181, 2002. View at Publisher · View at Google Scholar · View at Scopus
  180. N. G. Mahon, J. B. Young, and W. J. McKenna, “Beta adrenergic blockers in chronic congestive cardiac failure: a call for action,” European Journal of Internal Medicine, vol. 13, no. 2, pp. 96–100, 2002. View at Publisher · View at Google Scholar · View at Scopus
  181. R. S. Khattar, “Effect of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure,” Minerva Cardioangiologica, vol. 51, no. 2, pp. 143–154, 2003. View at Google Scholar · View at Scopus
  182. L. D. N. J. De Matos, G. Gardenghi, M. U. P. B. Rondon et al., “Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients,” Journal of Cardiac Failure, vol. 10, no. 6, pp. 496–502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  183. L. Gullestad, J. Hallen, J. I. Medbø, O. Grønnerød, I. Holme, and O. M. Sejersted, “The effect of acute vs chronic treatment with β-adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women,” British Journal of Clinical Pharmacology, vol. 41, no. 1, pp. 57–67, 1996. View at Publisher · View at Google Scholar · View at Scopus
  184. M. A. Van Baak, “β-Adrenoceptor blockade and exercise. An update,” Sports Medicine, vol. 5, no. 4, pp. 209–225, 1988. View at Publisher · View at Google Scholar · View at Scopus
  185. T. H. Westhoff, N. Franke, S. Schmidt et al., “Beta-blockers do not impair the cardiovascular benefits of endurance training in hypertensives,” Journal of Human Hypertension, vol. 21, no. 6, pp. 486–493, 2007. View at Publisher · View at Google Scholar · View at Scopus
  186. D. Ladage, R. H. G. Schwinger, and K. Brixius, “Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity,” Cardiovascular Therapeutics, vol. 31, no. 2, pp. 76–83, 2013. View at Publisher · View at Google Scholar · View at Scopus
  187. L. M. A. B. Van Bortel and M. A. van Baak, “Exercise tolerance with nebivolol and atenolol,” Cardiovascular Drugs and Therapy, vol. 6, no. 3, pp. 239–247, 1992. View at Publisher · View at Google Scholar · View at Scopus
  188. P. A. Ades, P. G. S. Gunther, W. L. Meyer, T. C. Gibson, J. Maddalena, and T. Orfeo, “Cardiac and skeletal muscle adaptations to training in systemic hypertension and effect of beta blockade (metoprolol or propranolol),” The American Journal of Cardiology, vol. 66, no. 5, pp. 591–596, 1990. View at Publisher · View at Google Scholar · View at Scopus
  189. L. Dalla Libera, B. Ravara, V. Gobbo et al., “Skeletal muscle proteins oxidation in chronic right heart failure in rats: can different beta-blockers prevent it to the same degree?” International Journal of Cardiology, vol. 143, no. 2, pp. 192–199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  190. M. D. Witham, D. Sumukadas, and M. E. T. Mcmurdo, “ACE inhibitors for sarcopenia—as good as exercise training?” Age and Ageing, vol. 37, no. 4, pp. 363–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  191. A. S. Vanzelli, A. Medeiros, N. Rolim et al., “Integrative effect of carvedilol and aerobic exercise training therapies on improving cardiac contractility and remodeling in heart failure mic,” PLoS ONE, vol. 8, no. 5, Article ID e62452, 2013. View at Publisher · View at Google Scholar · View at Scopus